TRAW
Traws Pharma, Inc.Company with tickers: TRAW
CIK
1130598
CUSIP
68232V884
Shares Outstanding
15,150,669
Website
https://www.trawspharma.com
Investor Relations
https://www.ir.trawspharma.com/
13F Activity (30d)
3 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $6,946,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $4,912,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-6,946,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-7,107,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.53 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.53 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Single Reportable Segment | $226,000 | $226,000 | $2,790,000 |